Mohammed El-Kurdi, PhD, Vice President for Tissue Science, and Luc Verhees, Senior Vice President for Clinical, Pre-clinical and Medical Affairs, joined Acting CEO Eliane Schutte – Xeltis CDO since 2016 – and CTO and Co-founder Martijn Cox on Xeltis’ leadership team. Xeltis newly appointed leadership holds deep technology knowledge and industry development expertise, which are functional to the company’s next development phase.
“The extensive and grounded expertise of our newly appointed team is well placed to translate knowledge and understanding of our technology into ultimate applications for clinicians and their patients,” stated Schutte. “Xeltis is the only company in clinical trial phase for years in over 25 patients for a polymer-based restorative cardiovascular technology that centers of excellence around the world are researching,” she added.
Scientist and inventor El-Kurdi recently joined Xeltis with over 20 years of experience in cardiovascular bioengineering. He is inventor on 25+ patents, author of several peer-reviewed articles and member of U.S. and international scientific societies.
At Xeltis since January 2018 as Vice President for Clinical Affairs, Verhees is a consummate cardiovascular device technology development expert. He previously held several global management positions at blue-chip and start-up companies, focusing on new and breakthrough technologies within interventional cardiology, cardiac surgery and peripheral interventions.
